Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics


Alkermes plc - Ordinary Shares (ALKS): $28.19

0.37 (+1.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALKS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALKS POWR Grades

  • Value is the dimension where ALKS ranks best; there it ranks ahead of 91.18% of US stocks.
  • ALKS's strongest trending metric is Momentum; it's been moving up over the last 177 days.
  • ALKS ranks lowest in Momentum; there it ranks in the 32nd percentile.

ALKS Stock Summary

  • ALKS's went public 31.72 years ago, making it older than 85.07% of listed US stocks we're tracking.
  • The price/operating cash flow metric for ALKERMES PLC is higher than 98.3% of stocks in our set with a positive cash flow.
  • Over the past twelve months, ALKS has reported earnings growth of 449.24%, putting it ahead of 96.45% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ALKERMES PLC are LCTX, NATI, THRM, VICR, and KNSA.
  • ALKS's SEC filings can be seen here. And to visit ALKERMES PLC's official web site, go to www.alkermes.com.

ALKS Valuation Summary

  • ALKS's price/earnings ratio is -27.5; this is 218.53% lower than that of the median Healthcare stock.
  • ALKS's price/sales ratio has moved down 8.2 over the prior 243 months.

Below are key valuation metrics over time for ALKS.

Stock Date P/S P/B P/E EV/EBIT
ALKS 2023-03-24 3.9 4.2 -27.5 -28.9
ALKS 2023-03-23 3.8 4.1 -26.7 -28.1
ALKS 2023-03-22 3.8 4.1 -26.8 -28.2
ALKS 2023-03-21 3.9 4.2 -27.5 -28.9
ALKS 2023-03-20 3.9 4.2 -27.7 -29.1
ALKS 2023-03-17 3.8 4.1 -27.0 -28.4

ALKS Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 64.4%.
  • Its 4 year revenue growth rate is now at 52.95%.
  • Its 3 year cash and equivalents growth rate is now at 25.45%.
Over the past 34 months, ALKS's revenue has gone down $82,270,000.

The table below shows ALKS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,111.795 21.044 -158.267
2022-09-30 1,131.584 51.018 -129.14
2022-06-30 1,173.368 133.17 -94.154
2022-03-31 1,200.866 168.539 -61.654
2021-12-31 1,173.751 101.715 -48.169
2021-09-30 1,129.283 138.037 -91.684

ALKS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALKS has a Quality Grade of B, ranking ahead of 88.71% of graded US stocks.
  • ALKS's asset turnover comes in at 0.582 -- ranking 63rd of 680 Pharmaceutical Products stocks.
  • OTLK, AVEO, and LXRX are the stocks whose asset turnover ratios are most correlated with ALKS.

The table below shows ALKS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.582 0.835 -0.047
2021-06-30 0.576 0.836 -0.029
2021-03-31 0.556 0.835 -0.050
2020-12-31 0.557 0.828 -0.061
2020-09-30 0.641 0.845 -0.034
2020-06-30 0.646 0.844 -0.076

ALKS Price Target

For more insight on analysts targets of ALKS, see our ALKS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.50 Average Broker Recommendation 1.88 (Hold)

ALKS Stock Price Chart Interactive Chart >

Price chart for ALKS

ALKS Price/Volume Stats

Current price $28.19 52-week high $32.79
Prev. close $27.82 52-week low $21.75
Day low $27.74 Volume 1,400,400
Day high $28.27 Avg. volume 1,266,718
50-day MA $27.33 Dividend yield N/A
200-day MA $25.90 Market Cap 4.63B

Alkermes plc - Ordinary Shares (ALKS) Company Bio


Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.


ALKS Latest News Stream


Event/Time News Detail
Loading, please wait...

ALKS Latest Social Stream


Loading social stream, please wait...

View Full ALKS Social Stream

Latest ALKS News From Around the Web

Below are the latest news stories about ALKERMES PLC that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

Alkermes (NASDAQ:ALKS) delivers shareholders favorable 26% CAGR over 3 years, surging 8.0% in the last week alone

By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...

Yahoo | March 31, 2023

The Cream Of The Crop: 5 Biotech Stocks That Outrank Most Stocks

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

Yahoo | March 30, 2023

Acadia (ACAD) Down 10.9% Since Last Earnings Report: Can It Rebound?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 29, 2023

Alkermes Stock Sees Rising Relative Strength Rating

The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. See if Alkermes stock can continue to rebound and hit that benchmark.

Yahoo | March 28, 2023

Alkermes Named to Ragan Communications and PR Daily’s Top Places To Work 2023

Alkermes was recently named to Ragan Communications and PR Daily' list of Top Places to Work for 2023! If you are interested in joining Team Alkermes, check out our careers page: https://bit.ly/3J6TBA0

Yahoo | March 23, 2023

Read More 'ALKS' Stories Here

ALKS Price Returns

1-mo 3.68%
3-mo 7.88%
6-mo 22.83%
1-year 0.46%
3-year 102.81%
5-year -37.67%
YTD 7.88%
2022 12.34%
2021 16.59%
2020 -2.21%
2019 -30.87%
2018 -46.08%

Continue Researching ALKS

Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:

Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8065 seconds.